Taiji Group announced that Southwest Pharmaceutical, a holding subsidiary of the company, has received the “Drug Registration Certificate” for butorphinol tartrate injections issued by the State Drug Administration. The drug specifications are 1ml: 1mg, 2ml: 4mg. The registration classification is chemical class 3. The approval numbers are Sinopharm Standard H20265615 and Sinopharm Standard H20265616. This drug is a second-class psychotropic drug and is suitable for treating various types of cancer pain and pain after surgery. Southwest Pharmaceutical is the sixth company to receive approval for the production of this drug, and has invested a total of 9.2421 million yuan in R&D expenses.

Taiji Group announced that Southwest Pharmaceutical, a holding subsidiary of the company, has received the “Drug Registration Certificate” for butorphinol tartrate injections issued by the State Drug Administration. The drug specifications are 1ml: 1mg, 2ml: 4mg. The registration classification is chemical class 3. The approval numbers are Sinopharm Standard H20265615 and Sinopharm Standard H20265616. This drug is a second-class psychotropic drug and is suitable for treating various types of cancer pain and pain after surgery. Southwest Pharmaceutical is the sixth company to receive approval for the production of this drug, and has invested a total of 9.2421 million yuan in R&D expenses.